Close

High Throughput Membrane Protein Array Screening Services

The human genome contains ~21,000 distinct protein-coding genes, out of which ~5,360 code for membrane proteins. Membrane proteins are critical for many cellular processes, such as signaling transduction, ion transportation, pathogen interaction and 60% of drugs currently in the market target membrane proteins. The High Throughput Membrane Protein Array Screening Services is the leading solution for antibody and CAR-T specificity profiling. This cell-based array contains more than 5300 human membrane proteins assembled to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics. By testing antibodies or chimeric antigen receptor (CAR) T cells against an array of native proteins, you know exactly what specificity you are getting.

High Throughput Membrane Protein Array Screening Services

High Throughput Membrane Protein Array Screening Services uses the membrane protein library, flow cytometry, and unfixed cells for detection.

High Throughput Membrane Protein Array Screening Services 2

High Throughput Membrane Protein Array Screening Services make your projects successful.

High Throughput Membrane Protein Array Screening Services 3

High Throughput Membrane Protein Array Screening Services

With years of experience in membrane protein production, Creative Biolabs is dedicated to offering High Throughput Membrane Protein Array Screening Services to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics. Our strategies of High Throughput Membrane Protein Array Screening Services include 3 main steps: 1) optimize conditions for detecting antibody binding; 2) high throughput screening; 3) confirm all identified targets in a second flow cytometry titration experiment. Please contact us for more detailed information to know how we can help.

High Throughput Membrane Protein Array Screening Services workflow. Fig.1 High Throughput Membrane Protein Array Screening Services workflow. (Gerhart, 2020)

High Throughput Membrane Protein Array Screening Application

The screening service was validated by testing the specificity of antibodies with known membrane protein targets. The antibody against an ion channel (anti-P2X3) was tested. The known target for each of anti-P2X3 antibody was readily identified. The service also identified binding to an additional membrane protein, informing the final lead selection in this program to avoid off-target binding that could cause patient side effects.

Assess specificity and off-target binding of antibodies. Fig.2 Assess specificity and off-target binding of antibodies. (Huston-Paterson, 2016)

High Throughput Membrane Protein Array Screening identified off-target CAR-T cells. More than 5300 membrane proteins were expressed in HEK293T cells and then screened with soluble Fc-tagged proteins to assess binding.

Specificity identification and off-target binding of CAR-T. Fig.3 Specificity identification and off-target binding of CAR-T. (Lee, 2020)

The systematic array of the membrane proteome in live human cells provides a unique opportunity to test the function of each membrane protein in live cell-based assays, such as the identification of novel receptors for Zika and Ebola viruses.

High Throughput Membrane Protein Array Screening for pathogen receptor discovery. Fig.4 High Throughput Membrane Protein Array Screening for pathogen receptor discovery. (Huston-Paterson, 2016)

Frequently Asked Questions

Q: What does the array contain?
A: High Throughput Membrane Protein Array Screening contains more than 5,300 human membrane proteins natively expressed in human cells

Q: What’s cells expressed membrane proteins?
A: Membrane proteins were expressed in unfixed human cells including HEK293 cells and Avian QT6 cells.

Q: What are the deliverables that I will receive?
A: You will receive a detailed report containing the binding profiles of your antibodies/ligands/CAR-T and validation results on identified targets.

References

  1. Tan, Y.; et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021, 11(4):71.
  2. Gerhart, J.; et al. Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage. PLoS ONE, 2020, 15(7):e0234792.
  3. Huston-Paterson, D.J.; et al. Screening the Membrane Protein: A High-Throughput Platform for Identifying Membrane Protein Antibody Targets. Genetic engineering & biotechnology news. 2016, 36(15):18-19.
  4. Lee, J.; et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. The Journal of clinical investigation. 2020, 130(12):6317-6324.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

CONTACT US

USA:
Europe:
Call us at:
USA:
Europe:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us